trimethobenzamide (Tigan)
Jump to navigation
Jump to search
Introduction
Tradename: Tigan.
Indications
Dosage
250 mg PO/IM TID/QID 200 mg IM/PR every 6-8 hours.
Pediatrics: 100-200 mg/dose if 30-90 lbs..
Tabs: 100 & 250 mg.
Suppositories: 100 & 200 mg (taken off market 2007[5])
Injection: 100 mg/mL (2 mL, 20 mL).
Adverse effects
- common (> 10%)
- less common (1-10%)
- uncommon (< 1%)
- blood dyscrasias, hypersensitivity skin reactions, depression, hepatic impairment, opisthotonus, convulsions
More general terms
Component of
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Department of Veterans Affairs, VA National Formulary
restricted to use with apomorphine - ↑ FDA MedWatch http://www.fda.gov/medwatch/safety/2007/safety07.htm#trimethobenzamide
- ↑ 5.0 5.1 Prescriber's Letter 14(5): 2007 FDA Announces that Companies Must Stop Marketing Suppository Products Containing Trimethobenzamide Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230505&pb=PRL (subscription needed) http://www.prescribersletter.com